Semaglutide (Wegovy)

Semaglutide is the most effective weight loss medication currently available, with clinical trials demonstrating an average 15-20% body weight reduction over 68 weeks. Originally developed for type 2 diabetes (as Ozempic), it was approved for weight management at a higher dose (2.4mg weekly) under the brand name Wegovy.

Semaglutide works by mimicking GLP-1, a natural hormone that regulates appetite, food intake, and blood sugar. Patients consistently report dramatically reduced hunger, fewer cravings, and feeling satisfied with smaller portions. At hi-doctor.ai, our EU-licensed doctors evaluate your eligibility and guide you through the gradual dose escalation protocol.

Semaglutide mimics GLP-1, acting on receptors in the brain that control appetite and satiety. It slows gastric emptying (keeping you full longer), reduces hunger signals, and decreases food reward pathways. It also improves insulin sensitivity and cardiovascular markers.

Most common: nausea (especially in early weeks, typically resolves), diarrhea, constipation, headache. Gradual dose escalation minimizes GI side effects. Serious but rare: pancreatitis, gallbladder problems. Not for patients with personal/family history of medullary thyroid cancer.